Table 2.

Stereotactic Body Radiation Therapy for Treatment of Unresectable CRLM

Study	Design	Treatment	N	Prior treatments	Median OS (±SD#), months (95% CI)	Median PFS, months (95% CI)	Adverse events
van der Pool et al (2010)37	Prospective, single-center cohort	SBRT	20	Any	34*	11*	2 cases ≥ grade 3
Kress et al (2012)30	Retrospective, single-center cohort	SBRT	11	Any	16.1*	1-year LC: 72%	1 case ≥ grade 3
Scorsetti et al (2015)36	Prospective, phase 2	SBRT	42	Any	29.0 ±3.7 (21.8–36.2)	12 ±4.2 (3.8–20.2)	None ≥ grade 3
McPartlin et al (2017)38	Prospective, phase 1 and 2	SBRT	60	Any	16.0 (11.9–20.5)	10.8*	1 case ≥ grade 3
Doi et al (2017)31	Retrospective, single-center cohort	SBRT	24	Any	45*	NR	Not reported
Petrelli et al (2018)35	Systematic review	SBRT	656	Any	31.5*	11.5*	8.7% ≥ grade 3
Vernaleone et al (2019)32	Retrospective, single-center cohort	SBRT	38	Any	20.1 (±2.0)	6.6 (±0.9)	None ≥ grade 3
Flamerique et al (2020)33	Retrospective, single-center cohort	SBRT	22	Any	24*	NR	1 case ≥ grade 3
Py et al (2021)34	Retrospective, single-center cohort	SBRT	67	Any	53 (38–66)	1-year LC: 81.9% (70.2%-89.2%) 5-year LC: 13.1% (6.0%-23.0%)	3% ≥ grade 3

CRLM, colorectal liver-only or liver-dominant metastases; SBRT, stereotactic body radiation therapy; OS, overall survival; PFS, progression-free survival; LC, local control; NR, not reported.

^*95% CI and/or P value not reported.

^#Where available.